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The sweat test (ST) is regarded as the gold standard diagnostic test for cystic ﬁbrosis
(CF). Borderline STs (i.e. 40−60mmol/L) present particular difﬁculties, not only
in the clinical diagnosis of a patient, but also in terms of genetic counselling.
Borderline results are seen in 4% of STs; 23% of these patients will subsequently
be found to have two CFTR mutations, one of which is usually “mild”. As part
of a data audit required in order to maintain testing and reporting standards, we
correlated CFTR mutations in 124 patients referred to the NCMG with “borderline”
or “equivocal” STs, over a 12 year period from 1995 to 2007 inclusive. If not
originally provided, ST levels were sought retrospectively for the purpose of the
audit. ST levels were obtained for 96/124 (77%) of referrals. 39% (37/96) of
referrals with “borderline” STs actually had normal ST levels according to accepted
reference ranges. None of the referrals with normal STs had two CFTR mutations.
51% of referrals (49/96) were conﬁrmed to have borderline ST levels. Of these,
82% (40/49) had no mutation, 12% (6/49) had one classic mutation and 6% (3/49)
had 2 mutations (one classic and one mild). 10% (9/77) had ST levels in the
diagnostic range. The high proportion of referred “borderline” STs that actually
had normal levels indicates a problem with interpretation or use of ST guidelines
by clinicians. The implications for genetic testing services are: (1) data audit is
required in order to maintain testing and reporting standards (2) ST results should
be sought if not provided with a query CF referral (3) ST results should be obtained
before performing comprehensive mutation screening.
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Clinical features of two groups of Russian CF patients according to their genotypes
were analyzed. The group with severe genotypes consists of 257 patients with two
mutations of I and/or II classes, the second group with mild genotypes consists of
23 patients with at least one mutation of IV and/or V classes. The disease began
more frequent from digestion abnormalities among patients with severe genotypes,
and from bronchopulmonary complications among patients with mild genotypes
(p< 0.01). The age of diagnosis was signiﬁcantly higher in mild genotyped patients
than in severe genotyped patients (p< 0.001). The difference between the mean age
of the ﬁrst disease symptoms and the mean age of diagnosis was larger in the group
with mild genotypes (p< 0.001). The age of onset of the intestinal disease symptoms
was lower in severe genotyped patients than in mild genotyped patients (p< 0.05).
Severe progression of disease was at lower age in the group with two mutations
of I and/or II classes (p< 0.001). The decrease of nutrition status (p< 0.01),
the deterioration of pulmonary function (FVD<70%) (p< 0.025) and bronchial
colonisation with P.aeruginosa (p< 0.001) were diagnosed signiﬁcantly earlier in
patients with severe genotypes. Intestinal and hepatobiliary abnormalities were more
rare among patients with at least one mild mutation (p< 0.001). Meconium ileus
and distal intestinal obstructive syndrome were diagnosed only among patients with
severe genotypes. Liver disease (ﬁbrosis and cirrhosis) were more frequent in severe
genotyped patients than in the mild genotyped group (p = 0.056). The mean age of
patients with liver disease was lower in the group with severe genotypes (p = 0.099).
Supported by: Russian Found of Fundamental Researches (07−04–00090; 05−04–
48135).
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Aim: Recently new methodologies allow to identify mutations for large deletions in
CF alleles (CFTRdel) and to date the estimated frequency is 1−3%. In our Center
CFTRdel account for 4.2%of CF mutations. The aim of this study is to investigate
the possible genotype–phenotype association.
Methods: 490 alleles of 245 CF patients have been studied. Alleles not identiﬁed by
conventional methods (PCR OLA–DHPLC sequency) were studied with the MLPA
technique (SALSA CFTR MLPA kit, MRC Holland) in order to detect deletions
of entire exons. Clinical data-pancreas status, Pseudomonas (Ps) infection, clinical
outcome-of patients carrying CFTRdel were examined.
Results: We identiﬁed CFTRdel in 21alleles, characterizing 20 CF patients, mean
age19.5 years (0.5−40).
Three different deletion types were found: CFTRdel22−23−24 (11/21 alleles),
CFTRdele2 (7/21 alleles), CFTRdele14b-17b, and CFTRdele 2−3.
Mutations carried on the other allele were F508del (12/20), G542X (2/20), L1065P,
G1244E, 2789+5G>A, R347P. Two patients presented private mutations (F311del
and S737F); one was homozygous CFTRdel22−23−24.
Except for two with private mutations, all patients presented pancreatic insufﬁciency
(90%). PS chronic infection was present in 15/20 (75%), and in 10/12 (83%)
F508del heterozygous. Ps ﬁrst isolation was precocious (mean age 3.4 y, range
0.5−11).
Four patients underwent a double lung transplantation (mean age 30 y) and two
died in waiting list (mean age 20 y) ﬁve of them were compound heterozygous for
F505del.
Conclusion: To date little is known about the effect of CFTRdel. We report clinical
features in 20 CF patients: most of them had pancreas insufﬁciency, early Ps
colonisation, chronic Ps infection, poor clinical outcome. These data seem to suggest
that CFTRdel correlate with severe phenotype.
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Comprehensive CFTR gene studies allow identifying both CF alleles in more than
98% of CF patients. De novo mutations are exceptional, but have been reported. In
order to assess their frequency, data from three French reference laboratories (Brest,
Creteil, Montpellier) were collected: 2250 families including CF patients with two
identiﬁed mutations and their parents, i.e. 4500 chromosomes.
Four cases of de novo mutations, all occurring on the paternal chromosome, were
documented by analysis of microsatellite markers located within the CFTR gene
and on various chromosomes: (1) E116K, in trans of F508del in a 21 y old
woman having DB, Pa colonization and positive ST; (2) 296+1G>T, in trans of
3272−26A>G A, in a 10 y old girl with severe ENT manifestations and positive
ST; (3) 3200–3204delTAGTG, in trans of F508del, in a girl diagnosed through NBS
(positive IRT and ST); (4) a partial duplication of exons 7 and 8 in trans of F508del
in a boy detected through NBS and identiﬁed by cDNA analysis.
While E116K was already reported in another CF patient, the three other mutations
were never described.
In conclusion, this study allowed estimating the frequency of CFTR de novo muta-
tions to 1 in 1100 chromosomes. These data are important for genetic counselling
and reﬂect the need to carry on systematic family studies, especially when private
mutations are identiﬁed or in cases of fetal hyperechogenic bowel during pregnancy
where study of foetal DNA should be recommended.
